Latest News

Latest News

News from the World Hepatitis Alliance

WHA in official relations with WHO: What does this mean for you?

28 Feb 2015 Bridie Taylor

Fundamental to our ability to influence global hepatitis policy and bring about real change in the world of hepatitis is our relationship with the...

What is the future for hepatitis treatments? And how we can fund hepatitis programmes?

28 Feb 2015 Bridie Taylor

Discussions around hepatitis are dominated by the pioneering new treatments rapidly transforming the landscape and the ensuing heated discussions...

How does the Alliance really represent hepatitis patients?

28 Feb 2015 Bridie Taylor

The World Hepatitis Alliance prides itself as the true voice of hepatitis patients living all over the world. All our work is overseen by an...

How will 2015 be a defining year for the Alliance?

28 Feb 2015 Bridie Taylor

Viral hepatitis is a global killer with alarming mortality rates, yet an increased global commitment to tackling the disease and ground-breaking new...

Need some inspiration for action? : Initiatives from WHA members

28 Feb 2015 Bridie Taylor

Together our voices are stronger and united we can tackle this global killer! The World Hepatitis Alliance is fortunate enough to be made up of...

Supporting the development of national action plans in South America

31 Jan 2015 Bridie Taylor

Government commitment to comprehensive national action plans is key to addressing the burden of viral hepatitis. To support the development of...

Promoting screening among high risk communities with new multi-lingual tool

31 Jan 2015 Bridie Taylor

In Europe, migrant populations are disproportionally affected by hepatitis B and C. Crucial to reducing the burden is improving screening among these...

Joining expert committees to promote harm reduction

31 Jan 2015 Bridie Taylor

Harm reduction policies are proven to save lives. Globally, as many as 67% of People Who Inject Drugs (PWIDs) have hepatitis C and an additional 8.4...

World Hepatitis Alliance’s ever-growing membership base

31 Jan 2015 Bridie Taylor

Central to the success of the World Hepatitis Alliance are our member groups around the world. To stimulate political interest in and action on...

Exploring new treatment developments and innovative ways to finance healthcare

31 Jan 2015 Bridie Taylor

New therapeutic developments are revolutionising the way hepatitis is treated. But with a global lack of funding, how can these pioneering new drugs...

Assisting WHO in the development of a global strategy

31 Jan 2015 Bridie Taylor

World Health Organization Member States have urged WHO to develop a comprehensive global strategy on hepatitis. To assist in the development of this...

Pages

News from infohep

Few countries will meet 2020 target for reducing viral hepatitis deaths

24 Nov 2020 Keith Alcorn
Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of...

Some hepatitis B patients can safely stop antivirals

24 Nov 2020 Liz Highleyman
Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead...

Can investment in hepatitis C treatment be cost saving?

24 Nov 2020 Keith Alcorn
Direct-acting antiviral treatment for hepatitis C can be cost saving for some countries within five to ten years, especially if they can negotiate...

Tenofovir alafenamide prevents mother-to-child hepatitis B virus transmission

20 Nov 2020 Liz Highleyman
Tenofovir alafenamide (TAF; Vemlidy) is highly effective at preventing transmission of hepatitis B virus (HBV) from mothers with a high viral load to...

Minimal monitoring of hepatitis C treatment is safe and effective

17 Nov 2020 Keith Alcorn
Hepatitis C treatment with no monitoring visits during treatment is safe and leads to a high cure rate, an international study reported on Monday at...

NASVAC therapeutic vaccine may lead to functional cure of hepatitis B

17 Nov 2020 Liz Highleyman
NASVAC, an experimental therapeutic vaccine that targets two different hepatitis B virus (HBV) antigens, led to a reduction in hepatitis B surface...

Fatty liver greatly increases vulnerability to COVID-19 in obese people

16 Nov 2020 Keith Alcorn
Fatty liver disease combined with obesity places people at much higher risk of severe COVID-19, analysis of British people who tested positive for...

Which people with chronic liver disease have higher COVID-19 risks?

16 Nov 2020 Keith Alcorn
Decompensated cirrhosis, alcoholic liver disease and hepatocellular carcinoma each raise the risk of death and severe illness from COVID-19 among...

Peers of drug users play key roles in hepatitis C treatment decision-making

4 Nov 2020 Keith Alcorn
Peers are important sources of information about hepatitis C treatment and may be the most persuasive advocates for engaging with treatment and care...

Cotadutide improves metabolic and liver biomarkers in people with NAFLD and diabetes

26 Oct 2020 Liz Highleyman
Cotadutide, an experimental therapy that alters glucose and lipid metabolism, led to weight loss and improvements in metabolic, cardiovascular and...